13th Euro Abstracts adherence/persistence and eight were able to improve the blood glucose levels of patients (double counting in three cases); fi ve had no effect at all. Four dimensions of the methodological quality of AI programs were identifi ed: 1) measurement of adherence/persistence/clinical outcomes, 2) measurement of NA/NP causes, 3) use of effective/validated intervention measures; and 4) effective program evaluation. The authors defi ned 5 detailed methodological requirements per dimension and, based on this, developed a corresponding scoring model (MIN Score 0, MAX score 20). All 19 AI programs were evaluated in the scoring model (average score 8.05): • Score <5: 3 AI-no adherence/blood glucose level improvement; • Score 5-9: 8 AI-6 with improvement in both adherence and/or blood glucose levels; • Score >9: 8 AI-all improved adherence and/or blood glucose levels. CONCLUSIONS: The scoring model provides a starting point for the methodical evaluation of AI. However, further development and testing of both the elements and construction is needed for medical indications other than diabetes type II. OBJECTIVES: To translate the MMAS into the Malaysian language, and to examine the psychometric properties of the Malaysian version of the MMAS among patients with type 2 diabetes, including its validity and reliability. METHODS: After obtaining permission, a standard "forward-backward" translation procedure was used to create the Malaysian version of the MMAS from the original English version. a convenience sample of 223 outpatients with type 2 diabetes was identifi ed between May and September, 2009. All data were collected from the Penang General Hospital, Penang, Malaysia. Instruments consisted of the Malaysian version of MMAS, the Malaysian version of the old four-item Morisky scale and a sociodemographic questionnaire. Medical records were reviewed for hemoglobin A1C (HbA1C) levels and other clinical data. Reliability was tested for internal consistency using Cronbach's α coeffi cient. Validity was confi rmed using convergent and known group validity. RESULTS: Employing the recommended scoring method, the mean ± SD of MMAS scores was 6.13 ± 1.72. Moderate internal consistency was found, (Cronbach's α = 0.675), the test-retest reliability value by using Spearman's rank correlation was 0.816 (P < 0.001). a positive correlation between the eight-and four-item MMAS was found (r = 0.792; P < 0.01). For known group validity, a signifi cant relationship between MMAS categories and HbA1c categories (χ2 = 20.261; P ≥ 0.001) was found. The MMAS sensitivity and specifi city, with positive and negative predictive values were 77.61%, 45.37%, 46.84% and 76.56%, respectively. CONCLUSIONS: The MMAS can be used for medication adherence measurement in diabetes. The fi ndings of this validation study indicate that the Malaysian version of the MMAS is a reliable and valid measure of medication adherence which can now be used in clinical practice.
1 National Institute of Public Health and the Environment, Bilthoven, The Netherlands; 2 Leids UniversityMedical Centre, Leiden, The Netherlands; 3 National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; 4 University of York, York, UK OBJECTIVES: The last decade several studies have proven that lifestyle interventions can be effective for people with or at risk for diabetes. Because effectiveness of preventive interventions is affected by non-participation (adherence), it is important to understand factors infl uencing people's willingness to participate in a lifestyle intervention. Therefore, the aim of this exploratory analysis is to examine which factors of a lifestyle program infl uence its valuation and willingness to participate. METHODS: We used conjoint analysis to empirically examine associations between the factors that infl uence participation and participants' valuation of an intervention and participants' willingness to participate in a lifestyle intervention. For this purpose participants received a questionnaire with four hypothetical lifestyle interventions. They were asked to value the hypothetical scenarios with a grade from "1" to "10" and furthermore they were asked if they would be willing to participate in these hypothetical programs. Linear and logistic regression techniques were used for the analyses. RESULTS: The factors "group activity," "counselling," and "receiving money" were positively associated with the scores of the valuation of the programmes. Logistic regression analysis showed that money was the only factor that was independently associated with respondents' willingness to participate in a lifestyle intervention. Subgroup analysis showed that receiving an amount of money was not associated with willingness to participate, but having to pay is negatively associated with participation in the lifestyle intervention. CONCLUSIONS: It appeared that only fi nancial disincentives were independently associated with willingness to participate in a lifestyle intervention. Our conjoint analysis results suggest that fi nancial incentives, in the form of bonuses, cannot be used to encourage people to participate in lifestyle interventions. Financial incentives, in the form of payments might however discourage participation, regardless of the content of the program.
PDB68 HEALTH RELATED QUALITY OF LIFE (HRQL) AND EQ-5D UTILITIES IN A TYPE 2 DIABETES (T2D) POPULATION: RESULTS FROM A SWEDISH SURVEY
Sörngård H 1 , Lagging E 2 , Lindh A 3 , Jörgensen L 1 1 AstraZeneca Nordic MC, Södertälje, Sweden; 2 Stockholm Diabetic Patient Association, Stockholm, Sweden, 3 Husläkarna i Österåker, Åkersberga, Sweden OBJECTIVES: To present HRQL data from a previously presented survey on T2D patients' perceived quality of care in Stockholm, Sweden. METHODS: A postal survey including EQ-5D was distributed to 1000 members of the Stockholm Diabetic Patient Association and 1000 patients from fi ve primary health care centers. Patients were randomly selected, >18 years, having a diabetes diagnosis. Analysis of variance was used to test the statistical hypothesis that patients within each subgroup had equal mean utility. RESULTS: Response rate was 65% (1319/2000 questionnaires). T2D diagnose was reported for 961 respondents of which 858 completed the EQ-5D questionnaire. Mean age 69 years, 48.5 % female, BMI 28.4 kg/m 2 , mean duration of T2D 11.3 years. Overall, the mean (SD) utility was 0.765 (0.260) and the current health status reported on the VAS scale was 0.727 (0.189). Patients without any hypoglycemic episode the previous month had a utility of 0.799 while those with 1, 2-5 or >5 episodes reported 0.774, 0.687 and 0.633, respectively. More than one hypoglycemic episode resulted in signifi cantly lower utility compared to none or only one episode (P < 0.0001). The utility of obese patients, 0.704, was signifi cantly lower than for patients of normal weight, 0.806, or overweight, 0.790 (P < 0.0001). The utility of patients not considering themselves responsible for the management of their T2D was signifi cantly lower, 0.608, compared to patients taking a limited, 0.774, or full, 0.759, responsibility (P = 0.0005). Patients considering themselves having insuffi cient knowledge to cope with their T2D reported a lower utility, 0.689, compared to patients with suffi cient knowledge, 0.789 (P < 0.0001). Male respondents had a higher utility, 0.796, compared to females, 0.731 (P = 0.0002). CONCLUSIONS: Experience of hypoglycemic episodes, obesity, gender, patients' perception of personal responsibility and perceived knowledge about type 2 diabetes has signifi cant impact on health related quality of life in patients with type 2 diabetes.
PDB69 UTILITY VALUES FOR DIABETES COMPLICATIONS
Donatti C, Lloyd A, Henry N, Grant D IMS Health, London, UK OBJECTIVES: Cost-utility analysis in diabetes requires utility estimates for diabetic complications. Models frequently rely on UKPDS data. UK requirements for preference elicitation have changed since UKPDS publication. We conducted a systematic review of the literature to identify utility values for diabetes complications suitable for use in Health Technology Assessment (HTA). METHODS: A systematic search of online databases was conducted using key words relating to diabetes, major complications, utility assessment and quality of life. Reference lists of identifi ed citations were reviewed. Studies reporting utility single-index measures in patients with any of 33 pre-specifi ed diabetes related states were included: states considered were diabetic complications and adverse events associated with anti-diabetic therapies (AEs). Papers were qualitatively assessed: criteria included relevance of studied population to Type 1 or Type 2 diabetes, sample size, methodological quality and consistency with current UK HTA guidelines. Comorbidity is common in diabetes: methodology papers addressing combination of utility values were identifi ed in a structured search and reviewed. RESULTS: The search returned 3024 hits, 169 articles were reviewed and 32 publications were identifi ed as suitable for review. Utility or disutility values suitable for UK HTA were obtained for 23 diabetes states. For 10 complications, including late stage renal disease and some AEs, no utility value were identifi ed that met UK HTA criteria. There is no consensus in the literature on how utility measures should be combined in patients with more than one complication. CONCLUSIONS: We identifi ed a set of utility values suitable for economic analysis for HTA in diabetes. To further inform UK HTA, additional research should create robust utility values for diabetic renal disease, and evaluate the empirical accuracy of alternative methods of combining utility values in patients with multiple complications.
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MEASUREMENT OF HRQOL USING EQ-5D IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH ORAL ANTI-DIABETIC DRUGS IN CHINA
Li HC 1 , Chang JH 2 , Liu GG 3 1 China Pharmaceutical University, Nanjing, China; 2 Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China, 3 Peking University, Beijing, China OBJECTIVES: The study is to measure the health-related quality of life (HRQOL) in type 2 diabetes mellitus (T2DM) patients with oral anti-diabetic drugs (OADs) therapy using the Chinese version of EQ-5D, and examine their health status. METHODS:
The study was a cross-sectional survey conducted at 75 hospitals in nine cities in China. There were 9577 T2DM patients administered with OADs therapy completed the questionnaires. The survey period was from December 3 rd , 2008 to July 31 st , 2009. Patients evaluated their health status using fi ve dimensions (5D) and a visual analog scale (VAS). Descriptive statistics was used to describe patients' demographic characteristics, duration of the disease, the frequency of 5D responses and VAS score. STATA 9.2 was used for the analyses. RESULTS: The mean age of patients (±SD) was 59.5 ± 12.7 years. 51.1% were male. The mean body mass index (±SD) was 24.3 ± 3.4 kg/ m 2 . The mean duration of disease (±SD) was 7.9 ± 6.3 years. For the fi ve dimensions
